In CML Patients With New Diagnoses, STAMP Inhibitor Outperforms Imatinib and Second-Gen TKIs.

Published Date: 03 Jun 2024

According to experts, the benefit-risk profile may alter the way CML is treated.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

2.

Report: Breast cancer mortality continues three decade decline, but steeper increases in incidence for some women

3.

PSA Screening May Modestly Curb Prostate Cancer Deaths

4.

Improved end-of-life conversations for cancer patients are identified by a new study.

5.

Enhanced CAR T cell therapy offers new strategy for lymphoma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot